Completed NA INTERVENTIONAL NCT00003903

Effect of Androgen Suppression on Bone Loss in Patients With or Without Bone Metastases Secondary to Prostate Cancer

An Evaluation of the Effect of Androgen Ablation on Bone Resorption in Prostate Cancer Patients

Sponsor: National Cancer Institute (NCI)

Interventions management of therapy complications

Updated 5 times since 2017 Last updated: Oct 14, 2013 Started: Jul 31, 1999 Primary completion: Aug 31, 2007 Completion: Aug 31, 2007

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This NA trial investigates Osteoporosis and Prostate Cancer and is currently completed. National Cancer Institute (NCI) leads this study, which shows 5 recorded versions since 1999 — indicating limited longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.

Status Flow

Change History

5 versions recorded

Sep 2024 — Present [monthly]

Completed NA
Jul 2024 — Sep 2024 [monthly]

Completed NA
Jan 2021 — Jul 2024 [monthly]

Completed NA
Jun 2018 — Jan 2021 [monthly]

Completed NA
Jan 2017 — Jun 2018 [monthly]

Completed NA

First recorded

Jul 1999

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

National Cancer Institute (NCI)
University of Rochester

Data source: University of Rochester

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Rochester, United States